Oral immunotherapy improves the quality of life of adults with food allergy.
Adults
Food allergy
Oral immunotherapy
Quality of life
Journal
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
ISSN: 1710-1484
Titre abrégé: Allergy Asthma Clin Immunol
Pays: England
ID NLM: 101244313
Informations de publication
Date de publication:
14 Oct 2024
14 Oct 2024
Historique:
received:
25
07
2024
accepted:
25
09
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
14
10
2024
Statut:
epublish
Résumé
Oral immunotherapy (OIT) has become the standard of care for children with food allergy (FA) and has substantially improved their quality of life. The effect of OIT on the quality of life in adults, however, has been studied to a much lesser degree. Patients with food allergy aged ≥ 18 years who underwent OIT at Shamir Medical Center completed the Food Allergy Quality of Life Questionnaire-Adult Form (FAQLQ-AF) before and at the end of treatment. Adults with FA not undergoing OIT who completed the FAQLQ-AF at 2 time points, served as controls. A total of 44 adults, median age 23.4 years, who underwent OIT for milk (n = 19), egg (n = 2), peanut (n = 9), sesame (n = 6), and tree nuts (n = 8), and 11 controls were studied. The median OIT starting dose was 23.8 mg protein. 33 patients (75%) reached full desensitization within a median of 10.3 months. The FAQLQ-AF baseline scores were comparable between the study and control groups for all items except for Food Allergy related Health (FAH) item in which the study group had a significantly better score (p = 0.02). At the second time point, the study group had significantly better scores in all items (Allergen Avoidance and Dietary Restrictions (AADR), p = 0.02; and Emotional Impact (EI), Risk of Allergen Exposure (RAE), FAH and the Total Score, p < 0.01). The change in scores for the study group was significantly better, statistically and clinically, in AADR, p = 0.04; EI, p < 0.01; RAE, p = 0.01, and in the total score, p = 0.01. OIT significantly improves quality of life of adults with FA. This finding adds important support for providing OIT in this population.
Sections du résumé
BACKGROUND
BACKGROUND
Oral immunotherapy (OIT) has become the standard of care for children with food allergy (FA) and has substantially improved their quality of life. The effect of OIT on the quality of life in adults, however, has been studied to a much lesser degree.
METHODS
METHODS
Patients with food allergy aged ≥ 18 years who underwent OIT at Shamir Medical Center completed the Food Allergy Quality of Life Questionnaire-Adult Form (FAQLQ-AF) before and at the end of treatment. Adults with FA not undergoing OIT who completed the FAQLQ-AF at 2 time points, served as controls.
RESULTS
RESULTS
A total of 44 adults, median age 23.4 years, who underwent OIT for milk (n = 19), egg (n = 2), peanut (n = 9), sesame (n = 6), and tree nuts (n = 8), and 11 controls were studied. The median OIT starting dose was 23.8 mg protein. 33 patients (75%) reached full desensitization within a median of 10.3 months. The FAQLQ-AF baseline scores were comparable between the study and control groups for all items except for Food Allergy related Health (FAH) item in which the study group had a significantly better score (p = 0.02). At the second time point, the study group had significantly better scores in all items (Allergen Avoidance and Dietary Restrictions (AADR), p = 0.02; and Emotional Impact (EI), Risk of Allergen Exposure (RAE), FAH and the Total Score, p < 0.01). The change in scores for the study group was significantly better, statistically and clinically, in AADR, p = 0.04; EI, p < 0.01; RAE, p = 0.01, and in the total score, p = 0.01.
CONCLUSIONS
CONCLUSIONS
OIT significantly improves quality of life of adults with FA. This finding adds important support for providing OIT in this population.
Identifiants
pubmed: 39402617
doi: 10.1186/s13223-024-00915-6
pii: 10.1186/s13223-024-00915-6
doi:
Types de publication
Journal Article
Langues
eng
Pagination
53Informations de copyright
© 2024. The Author(s).
Références
Patel N, Herbert L, Green TD. The emotional, social, and financial burden of food allergies on children and their families. Allergy Asthma Proc. 2017;38(2):88–91.
pubmed: 28234046
doi: 10.2500/aap.2017.38.4028
Bilaver LA, Chadha AS, Doshi P, O’Dwyer L, Gupta RS. Economic burden of food allergy: a systematic review. Ann Allergy Asthma Immunol. 2019;122(4):373-380.e1.
pubmed: 30703439
doi: 10.1016/j.anai.2019.01.014
Peters RL, Krawiec M, Koplin JJ, Santos AF. Update on food allergy. Pediat Allergy Immunol. 2021;32(4):647–57.
doi: 10.1111/pai.13443
Calvani M, Bianchi A, Imondi C, Romeo E. Oral desensitization in IgE-mediated food allergy: effectiveness and safety. Pediatr Allergy Immunol. 2020;31:49–50.
pubmed: 32017216
doi: 10.1111/pai.13171
Nowak-Wegrzyn A, Sato S, Fiocchi A, Ebisawa M. Oral and sublingual immunotherapy for food allergy. Curr Opin Allergy Clin Immunol. 2019;19(6):606–13.
pubmed: 31524655
doi: 10.1097/ACI.0000000000000587
Blumchen K, Trendelenburg V, Ahrens F, Gruebl A, Hamelmann E, Hansen G, et al. Efficacy, safety, and quality of life in a multicenter, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol Pract. 2019;7(2):479-491.e10.
pubmed: 30423449
doi: 10.1016/j.jaip.2018.10.048
Epstein-Rigbi N, Goldberg MR, Levy MB, Nachshon L, Elizur A. Quality of life of children aged 8–12 years undergoing food allergy oral immunotherapy: child and parent perspective. Allergy. 2020;75(10):2623–32.
pubmed: 32350869
doi: 10.1111/all.14350
Epstein-Rigbi N, Goldberg MR, Levy MB, Nachshon L, Elizur A. Quality of life of food-allergic patients before, during, and after oral immunotherapy. J Allergy Clin Immunol Pract. 2019;7(2):429-436.e2.
pubmed: 30129441
doi: 10.1016/j.jaip.2018.06.016
Pajno GB, Fernandez-Rivas M, Arasi S, Roberts G, Akdis CA, Alvaro-Lozano M, et al. EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. 2018;73(4):799–815.
pubmed: 29205393
doi: 10.1111/all.13319
Bégin P, Chan ES, Kim H, Wagner M, Favron-Godbout C, Abrams EM, et al. CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy. Allergy Asthma Clin Immunol. 2020;16:20.
pubmed: 32206067
doi: 10.1186/s13223-020-0413-7
pmcid: 7079444
Epstein-Rigbi N, Levy MB, Nachshon L, Koren Y, Katz Y, Goldberg MR, et al. Efficacy and safety of food allergy oral immunotherapy in adults. Allergy. 2023;78(3):803–11.
pubmed: 36190349
doi: 10.1111/all.15537
Bird JA, Spergel JM, Jones SM, Rachid R, Assa’ad AH, Wang J, et al. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract. 2018;6(2):476-485.e3.
pubmed: 29092786
doi: 10.1016/j.jaip.2017.09.016
Nurmatov U, Dhami S, Arasi S, Pajno GB, Fernandez-Rivas M, Muraro A, et al. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. Allergy. 2017;72(8):1133–47.
pubmed: 28058751
doi: 10.1111/all.13124
Rigbi NE, Goldberg MR, Levy MB, Nachshon L, Golobov K, Elizur A. Changes in patient quality of life during oral immunotherapy for food allergy. Allergy. 2017;72(12):1883–90.
pubmed: 28542911
doi: 10.1111/all.13211
Sicherer SH, Warren CM, Dant C, Gupta RS, Nadeau KC. Food allergy from infancy through adulthood. J Allergy Clin Immunol Pract. 2020;8(6):1854–64.
pubmed: 32499034
doi: 10.1016/j.jaip.2020.02.010
pmcid: 7899184
Elizur A, Appel MY, Goldberg MR, Yichie T, Levy MB, Nachshon L, et al. Clinical and laboratory 2-year outcome of oral immunotherapy in patients with cow’s milk allergy. Allergy. 2016;71(2):275–8.
pubmed: 26482941
doi: 10.1111/all.12794
Nachshon L, Goldberg MR, Levy MB, Appel MY, Epstein-Rigbi N, Lidholm J, et al. Efficacy and safety of sesame oral immunotherapy-a real-world, single-center study. J Allergy Clin Immunol Pract. 2019;7(8):2775-2781.e2.
pubmed: 31150789
doi: 10.1016/j.jaip.2019.05.031
Nachshon L, Goldberg MR, Katz Y, Levy MB, Elizur A. Long-term outcome of peanut oral immunotherapy-real-life experience. Pediatr Allergy Immunol. 2018;29(5):519–26.
pubmed: 29698554
doi: 10.1111/pai.12914
Elizur A, Appel MY, Nachshon L, Levy MB, Epstein-Rigbi N, Pontoppidan B, et al. Walnut oral immunotherapy for desensitisation of walnut and additional tree nut allergies (Nut CRACKER): a single-centre, prospective cohort study. Lancet Child Adolesc Health. 2019;3(5):312–21.
pubmed: 30926371
doi: 10.1016/S2352-4642(19)30029-X
Elizur A, Appel MY, Nachshon L, Levy MB, Epstein-Rigbi N, Koren Y, et al. Cashew oral immunotherapy for desensitizing cashew-pistachio allergy (NUT CRACKER study). Allergy. 2022;77(6):1863–72.
pubmed: 35000223
doi: 10.1111/all.15212
Levy MB, Elizur A, Goldberg MR, Nachshon L, Katz Y. Clinical predictors for favorable outcomes in an oral immunotherapy program for IgE-mediated cow’s milk allergy. Ann Allergy Asthma Immunol. 2014;112(1):58-63.e1.
pubmed: 24331395
doi: 10.1016/j.anai.2013.10.001
Flokstra-De Blok BMJ, Van Der Meulen GN, Dunngalvin A, Vlieg-Boerstra BJ, Oude Elberink JNG, Duiverman EJ, et al. Development and validation of the food allergy quality of life questionnaire—adult form. Allergy. 2009;64(8):1209–17.
pubmed: 19210345
doi: 10.1111/j.1398-9995.2009.01968.x
Nachshon L, Goldberg MR, Elizur A, Levy MB, Schwartz N, Katz Y. A Web site-based reporting system for monitoring home treatment during oral immunotherapy for food allergy. Ann Allergy Asthma Immunol. 2015;114(6):510–5.
pubmed: 25940735
doi: 10.1016/j.anai.2015.04.007
Van Der Velde JL, Flokstra-De Blok BMJ, Vlieg-Boerstra BJ, Oude Elberink JNG, Dunngalvin A, Hourihane JO, et al. Development, validity and reliability of the food allergy independent measure (FAIM). Allergy. 2010;65(5):630–5.
pubmed: 19845570
doi: 10.1111/j.1398-9995.2009.02216.x
WHO. Process of translation and adaptation of instruments. J Investig Allergol Clin Immunol. 2017;27(6):363–369. https://terrance.who.int/mediacentre/data/WHODAS/Guidelines/WHODAS%202.0%20Translation%20guidelines.pdf & https://doi.org/10.18176/jiaci.0182 . Accessed 28 Jun 2017.
Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407–15.
pubmed: 2691207
doi: 10.1016/0197-2456(89)90005-6
Goossens NJ, Flokstra-De Blok BMJ, Van Der Meulen GN, Arnlind MH, Asero R, Barreales L, et al. Health-related quality of life in food-allergic adults from eight European countries. Ann Allergy Asthma Immunol. 2014;113(1):63-68.e1.
pubmed: 24795291
doi: 10.1016/j.anai.2014.04.004
Stensgaard A, Bindslev-Jensen C, Nielsen D, Munch M, DunnGalvin A. Quality of life in childhood, adolescence and adult food allergy: patient and parent perspectives. Clin Exp Allergy. 2017;47(4):530–9.
pubmed: 27976436
doi: 10.1111/cea.12849
Goossens NJ, Flokstra-de Blok BMJ, Vlieg-Boerstra BJ, Duiverman EJ, Weiss CC, Furlong TJ, et al. Online version of the food allergy quality of life questionnaire-adult form: validity, feasibility and cross-cultural comparison. Clin Exp Allergy. 2011;41(4):574–81.
pubmed: 21395879
doi: 10.1111/j.1365-2222.2011.03711.x
Elizur A, Goldberg MR, Levy MB, Nachshon L, Katz Y. Oral immunotherapy in cow’s milk allergic patients: course and long-term outcome according to asthma status. Ann Allergy Asthma Immunol. 2015;114(3):240-244.e1.
pubmed: 25595888
doi: 10.1016/j.anai.2014.12.006
Soller L, Carr S, Kapur S, Rex GA, McHenry M, Cook VE, et al. Real-world peanut OIT in infants may be safer than non-infant preschool OIT and equally effective. J Allergy Clin Immunol Pract. 2022;10(4):1113-1116.e1.
pubmed: 34954121
doi: 10.1016/j.jaip.2021.12.009
Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol. 2017;139(1):173-181.e8.
pubmed: 27522159
doi: 10.1016/j.jaci.2016.05.027
Factor JM, Mendelson L, Lee J, Nouman G, Lester MR. Effect of oral immunotherapy to peanut on food-specific quality of life. Ann Allergy Asthma Immunol. 2012;109(5):348-352.e2.
pubmed: 23062391
doi: 10.1016/j.anai.2012.08.015
Blackman AC, Staggers KA, Kronisch L, Davis CM, Anagnostou A. Quality of life improves significantly after real-world oral immunotherapy for children with peanut allergy. Ann Allergy Asthma Immunol. 2020;125(2):196-201.e1.
pubmed: 32278075
doi: 10.1016/j.anai.2020.03.028
Hise K, Rabin RL. Oral immunotherapy for food allergy—a US regulatory perspective. Curr Allergy Asthma Rep. 2020;20(12):77.
pubmed: 33057855
doi: 10.1007/s11882-020-00973-x
Van der Velde JL, Flokstra-de Blok BMJ, Vlieg-Boerstra BJ, Oude Elberink JNG, Schouten JP, DunnGalvin A, et al. Test–retest reliability of the food allergy quality of life questionnaires (FAQLQ) for children, adolescents and adults. Qual Life Res. 2009;18(2):245–51.
pubmed: 19142745
doi: 10.1007/s11136-008-9434-2
Patel GB, Kellner ES, Clayton E, Chhiba KD, Alakija O, Bryce PJ, et al. Quality of life is lower in adults labeled with childhood-onset compared to adult-onset food allergy. Ann Allergy Asthma Immunol. 2021;127(1):70-75.e2.
pubmed: 33753218
doi: 10.1016/j.anai.2021.03.009
pmcid: 8483056
Van Der Velde JL, Flokstra-De Blok BMJ, De Groot H, Oude-Elberink JNG, Kerkhof M, Duiverman EJ, et al. Food allergy-related quality of life after double-blind, placebo-controlled food challenges in adults, adolescents, and children. J Allergy Clin Immunol. 2012;130(5):1136-1143.e2.
pubmed: 22835403
doi: 10.1016/j.jaci.2012.05.037
Makatsori M, Miles A. The psychological impact of food allergy and undergoing a food challenge test in adult age. Eur Ann Allergy Clin Immunol. 2021;53(6):252–62.
pubmed: 33415964
doi: 10.23822/EurAnnACI.1764-1489.187
Höfer V, Dölle-Bierke S, Reinert R, Worm M. Influence of nut and peanut allergy on the quality of life of adults. Hautarzt. 2022;73(3):186–94.
pubmed: 35072740
doi: 10.1007/s00105-021-04939-6
DunnGalvin A, Hourihane JO, Frewer L, Knibb RC, Oude Elberink JNG, Klinge I. Incorporating a gender dimension in food allergy research: a review. Allergy. 2006;61(11):1336–43.
pubmed: 17002711
doi: 10.1111/j.1398-9995.2006.01181.x
Nachshon L, Schwartz N, Elizur A, Schon Y, Cheryomukhin M, Katz Y, et al. The prevalence of food allergy in young Israeli adults. J Allergy Clin Immunol Pract. 2019;7(8):2782-2789.e4.
pubmed: 31175962
doi: 10.1016/j.jaip.2019.05.046